首页> 外文期刊>Artificial cells, nanomedicine, and biotechnology. >Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation
【24h】

Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation

机译:尼索地平负载纳米结构脂质载体和固体脂质纳米颗粒口服给药的比较研究:制备,表征,渗透和药代动力学评估

获取原文
           

摘要

Nisoldipine (ND) has low oral bioavailability (5%) due to first-pass metabolism. Previously, solid lipid nanoparticles (SLNs) of ND were reported. In this study, nanostructured lipid carriers (NLCs) of ND are developed to enhance the oral bioavailability. ND-NLCs were prepared using hot homogenization-ultrasonication method, using oleic acid and trimyristate as liquid lipid and solid lipid, respectively. Prepared NLCs are evaluated for an optimal system using measuring size, zeta potential, entrapment efficiency, in-vitro release and in-situ absorption studies. Further, in vivo pharmacokinetic (PK) studies of NLC were conducted in rats comparison with SLN and suspension as controls. Size, ZP and EE of optimized NLCs were found to be 110.4?±?2.95?nm, –29.4?±?2.05?mV and 97.07?±?2.27%, respectively. Drug loaded into NLCs was converted to amorphous form revealed by differential scanning calorimeter (DSC) and X-ray diffractometry (XRD) technique and nearly spherical in shape by scanning electron microscopy (SEM) studies. Drug release and absorption of ND were prolonged from ND-NLCs and ND-SLNs. From the PK results, NLCs showed 2.46 and 1.09-folds improvement in oral bioavailability of ND compared with suspension and SLNs formulations, respectively. Taken together, the NLCs and SLNs are used as carriers for the enhancement of oral bioavailability of the ND.
机译:尼索地平(ND)的首过代谢具有较低的口服生物利用度(5%)。以前,已经报道了ND的固体脂质纳米颗粒(SLN)。在这项研究中,ND的纳米结构脂质载体(NLC)被开发来增强口服生物利用度。 ND-NLC采用热均质-超声法制备,分别以油酸和均苯三酸酯为液体脂质和固体脂质。通过测量尺寸,ζ电势,包封效率,体外释放和原位吸收研究,评估制备的NLC是否为最佳系统。此外,在大鼠中进行了NLC的体内药代动力学(PK)研究,将SLN和悬浮液作为对照。经优化的NLC的尺寸,ZP和EE分别为110.4±2.95nm,–29.4±2.05mV和97.07±2.27%。通过差示扫描量热仪(DSC)和X射线衍射仪(XRD)技术显示,装载到NLC中的药物转变为无定形形式,通过扫描电子显微镜(SEM)研究,其形状接近球形。 ND-NLCs和ND-SLNs延长了ND的药物释放和吸收。从PK结果来看,与悬浮液和SLNs制剂相比,NLCs分别显示ND的口服生物利用度提高了2.46倍和1.09倍。总之,NLC和SLN被用作载体,以增强ND的口服生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号